The Business Times
business-time-50

Medtech startup set to revolutionise cancer diagnostics

google-preferred-sourceAdd BT as a preferred source
Published Wed, Jan 21, 2015 · 09:50 PM

    Singapore

    A SINGAPORE-based medtech startup that is looking to bring low-cost, simple-to-use cancer diagnostics tests to the masses, is set to revolutionise the global cancer diagnostics market that is projected to hit some US$168.6 billion in 2020.

    VolitionRx has developed a blood-based - therefore non-invasive - test platform that can potentially diagnose a wide range of cancers including colorectal and prostate, two of the most common cancers affecting men and women globally, The Business Times has learnt.

    Startups

    TRENDING NOW

    Eugene Lai (left) says that he was sharing a view with Tan Chian Khong that the board needed a refresh and that it was not an explicit direction to resign.

    CSE Global independent director quits after clashes with chairman Eugene Lai over board refresh

    In the last round of bidding, the premium for Category B was S$980 more than that for Category A.

    Cat A COE rate exceeds Cat B for third time in 4 months; premiums largely down

    Siranudh Scott had caused an internet sensation with a video accusing his brother of allegedly abusing him during his childhood years.

    ‘I felt like dying’: Thai Singha beer scion speaks up after disclosure of alleged sexual abuse

    The suspension at Manulife comes amid a broader, coordinated crackdown on cross-border wealth channels.

    Manulife pulls loan product for rich Hong Kong clients after scrutiny

    Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
    Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
    View More